viewHemoGenyx Pharmaceuticals

HemoGenyx optimistic on CDX antibodies prospects

HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX antibodies during the first half

HemoGenyx is confident that its humanised mice will be of interest to large biopharmaceutical firms

HemoGenyx Pharmaceuticals PLC (LON:HEMO) said it was optimistic about the prospects for its CDX antibodies, which are under development, as it posted wider first-half losses.

The biopharmaceuticals group said that during the period, it had filed a patent for a new type of humanised mouse with a "chimeric mouse-human blood system" and had signed a development agreement, as well as receiving first data results, in relation to its CDX antibodies.

"Overall the board is very pleased with the progress being made, in particular the unlocking of opportunities for CDX antibodies, as well as the potential value that can be created through the company's new type of humanised mice," executive chairman Marc Feldmann said in a statement.

"Hemogenyx is confident that these humanised mice will be of interest to large biopharmaceutical companies and has the potential to form the basis of significant future collaborations and the company hopes to update shareholders on progress in this area," he added.

The group posted a pretax loss of £0.65mln in the six months to the end of June, up from a loss of £0.14mln a year ago, hit by administrative costs, which more than trebled to £0.7mln. The company’s therapies are still under development meaning the company is yet to produce any revenue.

Blood cancers hard to treat

Blood cancers are some of the most difficult to treat forms of the killer disease.

They take three major forms: Leukaemia, Lymphoma and Myeloma, all of which involve problems in a person’s bone marrow, the source of the cells in our blood - red, white or platelets.

The current standard of care treatment involves chemotherapy and radiotherapy and ultimately, in recurring cases, a bone marrow transplant.

Two major problems

All current treatments are dangerous, highly toxic and debilitating, with serious side effects.

Indeed, so traumatic is the transplant option that many patients are rejected on the grounds that they will not survive the conditioning process.

After that comes the problem of finding a donor.

Hemogenyx has developed products that deal with both problems and offer the possibility of transforming the current treatments for blood cancers, says Sandler.

Partially based around work undertaken by founder and chief executive Vladislav Sandler at Cornell University, which is now a shareholder in Hemogenyx, they target a market estimated to be currently worth between US$8bn - US$9bn.

CDX antibodies, the first product, tackle the pre-transplant, conditioning stage.

A more benign alternative to the current standard of care, it will eliminate chemotherapy and radiotherapy by targeting and killing only “unwanted” cells (not everything) and allowing many more people who would otherwise be deemed unfit enough to receive a transplant.

Pre-clinical trials on humanised animals have already proved it as a concept, says Sandler.

A Phase I clinical trial though only a safety study will give a good indication of its potential.

Trial patients will only have a few months to live and they will either survive after treatment or not.

Stem cell treatment

Hemogenyx’s second product effectively replaces a patient’s cancer-infected blood with a new, clean, supply generated from their own stem cells.

As these blood stem cells have not been through the body’s circulatory system, they have not accumulated the mutations or chromosome rearrangements that cause the cancer.

“In effect, they reset blood generation back to zero” says Sandler.

These blood stem-like cells can also be found in everybody’s liver, he adds.




Quick facts: HemoGenyx Pharmaceuticals

Price: 10.29998 GBX

Market: LSE
Market Cap: £44.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...


Investor Update: New 11-year supply deal for Sirius Minerals

Top stories from the Proactive Investors UK newsroom. Events group Live Company (LON:LVCG) has entered into an agreement with Nickelodeon to produce themed tours associated throughout the UK and Ireland. The tours will based around Nickelodeon brands, including Nick Jr. HemoGenyx...

on 12/6/19

3 min read